Mouse Anti-CPT1C Recombinant Antibody (CBCNC-331) (V2LY-1206-LY1007)
Basic Information
| Application | Note |
| IP | 1-2 µg per 100-500 µg of total protein (1 ml of cell lysate) |
| IF(ICC) | 1:50-1:500 |
| ELISA | 1:100-1:1,000 |
| IHC-P | 1:50-1:500 |
Formulations & Storage [For reference only, actual COA shall prevail!]
Target
Fatty acid beta-oxidation Source: UniProtKB-UniPathway
Fatty acid metabolic process Source: GO_Central
Regulation of postsynaptic membrane neurotransmitter receptor levels Source: Ensembl
A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.
Helical: 53-75
Mitochondrial intermembrane: 76-103
Helical: 104-126
Cytoplasmic: 127-803
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon
Submit a review
Loading...
Please try the standard protocols which include: protocols, troubleshooting and guide.
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols
Custom Antibody Labeling
We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).
Online InquiryContact us
